The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...
Bausch Health has recently changed its strategy for Bausch + Lomb, looking to sell the segment which has a market capitalization of nearly $8 billion. The potential sale of Bausch + Lomb is a break ...
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...
The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.